The impact of metabolic syndrome on hepatocellular carcinoma: a mendelian randomization study
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 14, 2025
Traditional
epidemiological
studies
are
susceptible
to
confounding
factors.
To
clarify
the
impact
of
metabolic
syndrome
and
its
diagnostic
components
on
hepatocellular
carcinoma,
we
conducted
a
preliminary
mendelian
randomization
analysis
with
as
exposures
carcinoma
outcome.
Another
set
genetic
data
related
was
used
validation
cohort,
repeating
combining
two
groups
for
meta-analysis.
Preliminary
showed
that
(P-value
=
0.002)
waist
circumference
0.026)
significantly
positively
correlated
an
increased
risk
carcinoma.
After
multiple
testing
corrections,
(PFDR-value
0.013)
remained
significant,
although
association
between
0.079)
considered
suggestive,
meta-analysis
further
confirmed
0.0002)
0.0038)
in
increasing
adjusting
predictive
effects
all
exposures,
found
be
key
factor
influencing
relationship
In
summary,
our
study
indicates
increases
particularly
among
individuals
larger
circumference.
Язык: Английский
Lipid Metabolism and Immune Response in Hepatocellular Carcinoma: Interplay Driving Tumor Progression
Опубликована: Апрель 4, 2025
With
the
rising
incidence
of
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
it
has
become
a
significant
risk
factor
for
hepatocellular
carcinoma
(HCC).
This
review
focuses
on
roles
lipid
metabolism
aberrations
and
reprogramming
in
HCC
development.
We
begin
with
brief
overview
relevant
lipids
to
HCC,
including
fatty
acyls,
glycerolipids,
glycerophospholipids
sterol
lipids,
discuss
particularly
how
associated
its
promotes
chemoresistance
HCC.
then
explore
heterogeneity
distribution
across
different
stages
includes
intra-tissue
spatial
histological
structure
zonated
regions
liver,
interpatient
tumor
at
various
degrees
resolutions,
from
single
cell
bulk
tissue
levels.
Next,
we
describe
plasticity
MASLD
advent
immunotherapy
also
examine
relationship
between
anti-tumor
immunity
Finally,
address
challenges
future
perspectives
targeting
as
dual
approach
improve
treatment.
Язык: Английский
Association between insulin glargine and risk of cancer: an updated and comprehensive systematic review and meta-analysis of observational studies
International Journal of Diabetes in Developing Countries,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 22, 2024
Язык: Английский
Hepatocyte nuclear factor 1 alpha variants as risk factor for hepatocellular carcinoma development with and without diabetes mellitus
Isis Samy Bedira,
Ibrahim El Tantawy El Sayed,
Olfat Hendy
и другие.
Gene Reports,
Год журнала:
2024,
Номер
37, С. 102078 - 102078
Опубликована: Ноя. 1, 2024
Язык: Английский
Transcriptomic and metabolomic analyses reveal the spatial role of carnitine metabolism in the progression of hepatitis B virus cirrhosis to hepatocellular carcinoma
Frontiers in Microbiology,
Год журнала:
2024,
Номер
15
Опубликована: Дек. 13, 2024
Introduction
Liver
cirrhosis
(LC)
and
hepatocellular
carcinoma
(HCC)
resulting
from
chronic
hepatitis
B
virus
(HBV)
infection
are
major
health
concerns.
Identifying
critical
biomarkers
molecular
targets
is
needed
for
early
diagnosis,
prognosis,
therapy
of
these
diseases.
Methods
In
this
study,
we
explored
the
gene
expression
metabolism
in
liver
tissues
LC,
HCC,
healthy
controls,
to
analyse
identify
potential
disease
progression.
Mass
spectrometry
imaging
was
used
evaluate
spatial
distribution
key
metabolites.
Results
discussion
The
results
revealed
significant
changes
metabolic
pathways
along
with
upregulated
genes
were
associated
extracellular
matrix
remodeling
cancer
pathways,
including
LAMC1-3,
COL9A2,
COL1A1,
MYL9,
MYH11,
KAT2A.
downregulated
linked
immune
response
fatty
acid
metabolism.
Metabolomic
analysis
showed
lipid
choline
Consistent
specific
metabolites
correlated
clinical
data.
Notably,
such
as
L-acetylcarnitine,
histamine,
4-trimethylammoniobutanoic
demonstrated
high
accuracy
(AUC
>
0.85)
distinguishing
between
healthy,
HCC
groups.
This
study
identifies
metabolite
HBV
related
LC
highlighting
involved
Biomarkers
like
L-acetylcarnitine
KAT2A
show
promise
diagnosis
potentially
improving
outcomes
patients.
Язык: Английский